Breaking News

WuXi Biologics, Boostimmune Ink MOU for Exclusive R&D Services

WuXi Biologics will be the exclusive service partner to support Boostimmune in generating different modality candidates.

WuXi Biologics, a global contract research, development, and manufacturing organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next-generation anti-cancer therapies, signed a memorandum of understanding (MOU) for research and discovery services for Boostimmune’s pipeline. Under the alliance, Boostimmune will have access to WuXi Biologics’ discovery services and expertise in antibody discovery, lead optimization, in vitro screening, and characterization...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters